Xilio Therapeutics, Inc. (XLO)
8.94
+0.03
(+0.34%)
USD |
NASDAQ |
Sep 09, 16:00
8.94
0.00 (0.00%)
After-Hours: 17:07
Xilio Therapeutics Enterprise Value : -71.11M for Sept. 8, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 08, 2026 | -71.11M |
| September 04, 2026 | -70.52M |
| September 03, 2026 | -70.38M |
| September 02, 2026 | -71.57M |
| September 01, 2026 | -71.31M |
| August 31, 2026 | -70.85M |
| August 28, 2026 | -70.52M |
| August 27, 2026 | -70.45M |
| August 26, 2026 | -70.19M |
| August 25, 2026 | -69.99M |
| August 24, 2026 | -69.27M |
| August 21, 2026 | -69.00M |
| August 20, 2026 | -69.00M |
| August 19, 2026 | -67.82M |
| August 18, 2026 | -67.23M |
| August 17, 2026 | -67.29M |
| August 14, 2026 | -69.40M |
| August 13, 2026 | -70.45M |
| August 12, 2026 | -70.19M |
| August 11, 2026 | -69.33M |
| August 10, 2026 | -69.20M |
| August 07, 2026 | -69.40M |
| August 06, 2026 | -68.74M |
| August 05, 2026 | -69.79M |
| August 04, 2026 | -69.92M |
| Date | Value |
|---|---|
| August 03, 2026 | -70.19M |
| July 31, 2026 | -69.79M |
| July 30, 2026 | -69.99M |
| July 29, 2026 | -69.86M |
| July 28, 2026 | -69.53M |
| July 27, 2026 | -69.92M |
| July 24, 2026 | -72.82M |
| July 23, 2026 | -75.06M |
| July 22, 2026 | -73.94M |
| July 21, 2026 | -72.49M |
| July 20, 2026 | -73.35M |
| July 17, 2026 | -71.31M |
| July 16, 2026 | -70.32M |
| July 15, 2026 | -69.73M |
| July 14, 2026 | -70.32M |
| July 13, 2026 | -68.94M |
| July 10, 2026 | -69.86M |
| July 09, 2026 | -69.20M |
| July 08, 2026 | -68.67M |
| July 07, 2026 | -68.48M |
| July 06, 2026 | -67.62M |
| July 02, 2026 | -69.53M |
| July 01, 2026 | -69.07M |
| June 30, 2026 | -66.70M |
| June 29, 2026 | -90.09M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Cue Biopharma, Inc. | 148.30M |
| ACADIA Pharmaceuticals, Inc. | 3.865B |
| Alnylam Pharmaceuticals, Inc. | 34.46B |
| Anika Therapeutics, Inc. | 268.42M |
| Savara, Inc. | 993.23M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -6.373M |
| Revenue (Quarterly) | 18.69M |
| Total Expenses (Quarterly) | 25.06M |
| EPS Diluted (Quarterly) | -0.3284 |
| Gross Profit Margin (Quarterly) | 98.23% |
| Profit Margin (Quarterly) | -34.09% |
| Earnings Yield | -18.86% |
| Normalized Earnings Yield | -20.14 |